The FDA has approved Epiduo for over-the-counter use, a combination acne gel previously available only by prescription, a decision experts say could expand access to effective treatment for the millions of Americans who face cost and logistical barriers to dermatological care.
Real-world data presented at ASCO also show that at 12 month and 24 months, patients treated with Brukinsa had a higher probability of survival than those treated with other BTK inhibitors.
Peterson Philanthropies announced a commitment of $50 million to set up the public benefit company that will provide employers with healthcare pricing and quality data.
C. Brooke Adams, Pharm.D., BCOP, of Orlando Health discusses bispecific antibody therapies for multiple myeloma.
Mike Badome is chief actuary of Arcadia, an outcomes company that helps healthcare organizations improve cost, quality and operational performance.
Bahar Davidoff, Pharm.D., MBA, is founder and principal of Davidoff Strategy and Consulting, a healthcare advisory firm focused on healthcare operations, pharmacy strategy and artificial intelligence (AI) integration.
Sham Firdausi, M.P.H., M.Sc., MBA, is deputy chief financial officer of the Santa Clara Valley Healthcare, one of the largest public health systems in the country and California’s second-largest county-owned health and hospital system.
Zach Jones, Pharm.D., is senior director of clinical formulary strategy, Prime Therapeutics, a Minnesota-based pharmacy benefit manager.
How Banjo Health uses generative AI to speed prior authorizations, cut paperwork, and scale fair, transparent utilization management across plans.
HaVy Ngo-Hamilton, Pharm.D., senior pharmacy director, Buzz Health, a healthcare technology company offering prescription savings solutions that integrate with health systems to promote price transparency and cost-effectiveness.
Brianna Oddi, Pharm.D. Brianna Oddi, Pharm.D., is senior clinical account manager of PANTHERx Rare Pharmacy
Carly Rodriguez, Pharm.D., is vice president and chief pharmacy officer, Moda Health and immediate past president of the Academy of Managed Care Pharmacy
Alyana Samai, M.P.H., is corporate vice president, neuroscience and musculoskeletal services, at LCMC Health, an eight-hospital, New Orleans-based nonprofit health system.
Lorece Shaw, Pharm.D., is director of clinical account consulting at Capital Rx, a pharmacy benefit and management company.
The second-line drug for metastatic pancreatic cancer is pan-RAS inhibitor that recruits cyclophilin A to stick to RAS proteins, explains Subham Pant, M.D., M.B.B.S., of The University of Texas MD Anderson Cancer Center.
Javier Cortes, M.D., Ph.D., discusses KEYNOTE-522 findings showing pembrolizumab plus chemotherapy delivers durable survival gains in high-risk early-stage TNBC after nearly 8 years of follow-up.
Eduardo Vilar-Sanchez, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, was awarded for his work in cancer immunoprevention and his efforts to develop a cancer vaccine for those who are carriers of Lynch mutations.
Treatment after treatment for second-line treatment for pancreatic cancer has failed in clinical trials. Daraxonrasib seems to have broken the losing streak, says MD Anderson's Shubman Pant, M.D., M.B.B.S.
Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody that achieved 28-month median survival in advanced squamous non-small cell lung cancer.
A phase 3 clinical trial presented at ASCO 2026 found that combining talazoparib with enzalutamide reduced the risk of cancer progression by 52% compared with enzalutamide alone in prostate cancer patients with specific DNA repair gene mutations, with even greater benefit seen in those carrying BRCA mutations.
Lead ARACOG trial investigator Alicia Morgans, M.D., discusses the importance of including cognitive effects in the conversation around prostate cancer treatment.
A new investigational combination therapy for advanced KRAS G12C-mutant non-small cell lung cancer showed "highly promising" results with “manageable” side effects, according to the study’s lead author.
Ferdinandos Skoulidis, M.D., Ph.D., explains what’s next for this treatment for patients with previously untreated advanced or metastatic KRAS G12C-mutated non-small cell lung cancer.
Divarasib plus pembrolizumab shows strong responses in patients with advanced KRAS G12C+ non-small cell lung cancer, according to the results of the Krascendo 170 study, presented today at ASCO 2026.
Dana-Farber’s Katherine Janeway, M.D., discusses how reimbursement policies for molecular diagnostics have failed to keep pace with scientific evidence, leaving gaps in the care for pediatric bone cancer patients.
A collagen implant that releases radiation after brain tumor surgery reduced cancer recurrence and increased overall survival, according to results presented at ASCO’s annual meeting.
Dana-Farber’s Katherine Janeway, M.D., discusses how molecular biomarkers inform treatment decisions in children and adolescents with the bone cancers Ewing sarcoma and osteosarcoma.
Seven-year CROWN trial data show Lorbrena's median PFS is still not reached in advanced ALK-positive NSCLC, with a 94% reduction in intracranial progression risk.
Afrezza is an inhaled insulin and the first needle-free insulin option for children with diabetes.
Because pharmacy benefit managers and third-party administrators earn more from arrangements with smaller safety-net providers, there are incentives to shift attribution of prescriptions toward those providers.
